{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:47:14Z","timestamp":1771879634925,"version":"3.50.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen deprivation therapy, the systemic treatments now include docetaxel, abiraterone, enzalutamide, and apalutamide. Radiation to the primary is also an option for select low-volume patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a review of the pivotal trials that have changed the practice of mHSPC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We describe an overview of the trials that investigated docetaxel (CHAARTED and STAMPEDE-Docetaxel), abiraterone (LATTITUDE and STAMPEDE-Abiraterone), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN), and radiation to the primary (STAMPEDE-Radiation).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The treatment of mHSPC is a complex topic, and treatment choice should be individualized. Patient preferences, cost, volume of disease, and side effect profiles are important in determining which option is the best for an individual patient.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ppo.0000000000000418","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:03:19Z","timestamp":1579892599000},"page":"64-75","source":"Crossref","is-referenced-by-count":34,"title":["Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1097","volume":"26","author":[{"given":"Emily N.","family":"Kinsey","sequence":"first","affiliation":[{"name":"Department of Medicine, Duke University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Divisions of Medical Oncology and Urology, Duke Cancer Institute, Durham, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1200\/JCO.2007.15.9830","article-title":"Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","year":"2018","journal-title":"Prostate"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/pcan.2016.30","article-title":"Increasing incidence of metastatic prostate cancer in the United States (2004\u20132013)","volume":"19","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162)","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00000658-194206000-00030","article-title":"Effect of orchiectomy and irradiation on cancer of the prostate","volume":"115","year":"1942","journal-title":"Ann Surg"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMc1410239","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","year":"2013","journal-title":"Lancet Oncol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamaoncol.2017.5808","article-title":"Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PREVAIL randomized clinical trial","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","article-title":"ARN-509: a novel antiandrogen for prostate cancer treatment","volume":"72","year":"2012","journal-title":"Cancer Res"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","article-title":"Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","article-title":"Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study","volume":"65","year":"2014","journal-title":"Eur Urol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","year":"2018","journal-title":"Ann Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","year":"2019","journal-title":"Eur Urol"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","year":"2017","journal-title":"Eur J Cancer"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","year":"2011","journal-title":"Lancet"},{"issue":"6 suppl 21","key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/sonc.2002.37418","article-title":"Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid","volume":"29","year":"2002","journal-title":"Semin Oncol"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C","article-title":"Expression of cyclooxygenase-2 in prostate carcinoma","volume":"89","year":"2000","journal-title":"Cancer"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(12)70088-8","article-title":"Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2016.69.0677","article-title":"Adding celecoxib with or without zoledronic acid for hormone-naive prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform randomized controlled trial","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.euf.2017.01.015","article-title":"Safety and antitumour activity of ODM-201 (BAY-1841788) in chemotherapy-naive and CYP17 inhibitor-naive patients: follow-up from the ARADES and ARAFOR trials","volume":"4","year":"2018","journal-title":"Eur Urol Focus"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","article-title":"Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial","volume":"15","year":"2014","journal-title":"Lancet Oncol"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2014.05.038","article-title":"Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial","volume":"66","year":"2014","journal-title":"Eur Urol"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/pcmedi\/pby018","article-title":"The promise of immunotherapy in genitourinary malignancies","volume":"1","year":"2018","journal-title":"Precis Clin Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:18:52Z","timestamp":1695532732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000418"}},"subtitle":["A Review of the Current Treatment Landscape"],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000418","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}